Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Background Daratumumab showed promising efficacy alone and with lenalidomide and
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with …

Background In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …

Daratumumab is a CD38‐targeting monoclonal antibody approved for intravenous (IV)
infusion for multiple myeloma (MM). We describe the Phase II PLEIADES study of a …

Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

The treatment of multiple myeloma has evolved markedly in the last decade, but mortality
remains high, emphasizing the need for more effective therapies. Daratumumab, a fully …

Background Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces
direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy …

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical
activity in combination with bortezomib and dexamethasone versus bortezomib and …

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly
reduced risk of progression/death versus lenalidomide/dexamethasone alone in …